Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Glucovance

Glucovance
In stock
400/2.50mg · 500/5mg
from A$69.76
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$83.71A$69.76
A$2.33 per tablet

In brief

  • In our pharmacy, you can buy Glucovance without a prescription, with delivery in 9–21 days throughout Australia. Discreet and anonymous packaging.
  • Glucovance is used to treat adults with type 2 diabetes as an adjunct to diet and exercise; it is a fixed‑dose combination of glyburide (glibenclamide), a sulfonylurea that stimulates pancreatic insulin secretion, and metformin, a biguanide that reduces hepatic glucose production and improves insulin sensitivity.
  • The usual dose is one 500 mg/5 mg tablet once or twice daily with meals (other strengths such as 500/2.5 mg and 1000/5 mg exist); dosing is individualised and may be adjusted by a clinician based on blood glucose response.
  • Form of administration: film‑coated oral tablet, taken with food to reduce gastrointestinal side effects and risk of hypoglycaemia.
  • Onset time: the glyburide component begins lowering blood glucose within about 1–2 hours, while metformin’s full glycaemic benefits usually develop over days to weeks.
  • Duration of action: glucose‑lowering effects last roughly 12–24 hours depending on dose and individual factors, which is why dosing is commonly once or twice daily.
  • Alcohol warning: avoid or limit alcohol—alcohol increases the risk of metformin‑associated lactic acidosis and can worsen hypoglycaemia from the sulfonylurea component; discuss alcohol use with a healthcare professional.
  • The most common side effect is hypoglycaemia (low blood sugar) due to the sulfonylurea; other frequent effects include gastrointestinal symptoms such as nausea, diarrhoea and abdominal discomfort from metformin.
  • Would you like to try Glucovance without a prescription?

Critical Warnings & Restrictions

Basic Glucovance Information

  • INN (International Nonproprietary Name): glibenclamide/metformin (also known as glyburide/metformin in North America).
  • Brand Names Available In Australia: GLUCOVANCE 500/5 (metformin HCl 500 mg + glibenclamide 5 mg) tablets in blister packs; recorded in the ARTG.
  • ATC Code: A10BD02.
  • Forms & Dosages: Film-coated oral tablets with fixed combinations; Australian ARTG lists the 500 mg/5 mg strength.
  • Manufacturers In Australia: not specified.
  • Registration Status In Australia: GLUCOVANCE 500/5 tablets are recorded in the Australian Register of Therapeutic Goods (ARTG).
  • OTC / Rx Classification: Prescription-only medicine.

Safety First — Major Risks, Contraindications, Monitoring

Patients often worry about low blood sugar and rare but serious metabolic effects.

Key alerts include the risk of hypoglycaemia from the glyburide (glibenclamide) component.

Key alerts also include the risk of lactic acidosis associated with metformin in people with significant renal impairment.

Other high-risk contexts for lactic acidosis are hepatic disease, severe dehydration and excessive alcohol use.

Stop and seek urgent care for severe hypoglycaemia such as sweating, confusion or loss of consciousness.

Also stop and seek urgent care for signs of lactic acidosis such as rapid breathing, severe malaise, myalgia or marked drowsiness.

Contraindications/High‑Risk Groups

  • Severe renal impairment — check eGFR regularly.
  • Acute or chronic metabolic acidosis.
  • Unstable heart failure.
  • Hepatic failure.
  • Heavy alcohol use.
  • Pregnancy and breastfeeding — consult an obstetrician.

Monitoring Checklist

  • Baseline renal function (eGFR) before starting treatment.
  • Baseline liver function tests (LFTs) where clinically indicated.
  • Baseline and periodic HbA1c to judge efficacy.
  • Regular self-monitoring of blood glucose (SMBG), especially initially.
  • Education on hypoglycaemia recognition and rescue — fast-acting carbohydrates and glucagon where indicated.

Interaction With Activities (Driving, Workplace Safety)

Hypoglycaemia can impair the ability to drive or safely operate machinery.

Australian road-safety guidance requires patients to manage and report medical conditions that affect safe driving.

Advise patients to discuss driving fitness with their GP and notify licensing authorities or an ophthalmologist where vision or hypoglycaemia awareness is affected.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: Only if there are no recent hypoglycaemia episodes and the patient understands typical blood glucose patterns and can recognise symptoms.

Patients who have had hypoglycaemia or who have impaired awareness of hypoglycaemia should discuss driving with their GP and the local licensing authority.

People should carry fast-acting carbohydrate and a glucose meter when driving until patterns are stable.

Usage Basics

INN & Active Ingredients

Glibenclamide (glyburide)
Sulfonylurea oral antihyperglycaemic.
Metformin Hydrochloride
Biguanide oral antihyperglycaemic.

Product information states: “Glucovance is a fixed‑dose oral antidiabetic combination of glyburide (glibenclamide) and metformin hydrochloride, indicated for adults with type 2 diabetes as an adjunct to diet and exercise, typically when monotherapy with metformin or a sulfonylurea is insufficient or when patients are already stable on the free combination of metformin + glibenclamide.”

Brand Names & Australian Presentation

In Australia the product is marketed as GLUCOVANCE.

The Australian product recorded in the ARTG is GLUCOVANCE 500/5, which contains metformin HCl 500 mg and glibenclamide 5 mg per tablet.

Tablets are supplied in blister packs for oral administration.

Legal Classification

Glucovance is a prescription-only medicine in Australia and requires a valid prescription for supply.

Patients should keep prescriptions for repeats and confirm subsidy status with the PBS where applicable.

Steps To Check PBS Listing:

  • Ask the GP to confirm whether the prescribed product is on the PBS and whether an authority is required.
  • Check the PBS Schedule online or ask the pharmacist to verify subsidy and patient co-payment.
  • If cost is a concern, discuss alternative PBS-listed options with the prescriber.

Dosing Guide

Principles & Typical Regimens

  • Start low and titrate: metformin is usually optimised first for tolerability and renal function.
  • Sulfonylurea (glyburide) dose adjusted to achieve glycaemic targets while minimising hypoglycaemia.
  • Fixed‑dose tablets such as the 500 mg/5 mg strength simplify combined dosing but reduce flexibility for separate titration.
  • Take with meals to reduce gastrointestinal upset and to lower hypoglycaemia risk.
  • Avoid skipping meals when taking sulfonylurea-containing products.

Adjustments For Comorbidities

  • Renal impairment — dose reduce or avoid per eGFR thresholds and specialist advice.
  • Hepatic disease — use caution and consider alternative therapies.
  • Elderly — start at lower doses due to increased hypoglycaemia risk.
  • Perioperative and sick days — metformin may need temporary cessation around contrast procedures or acute illness.

Q&A — “What If I Miss A Dose?”

If the missed dose is remembered the same day, take it as soon as possible with food.

Do not double up doses to make up for a missed tablet.

If it is near the time of the next scheduled dose, skip the missed dose and resume the usual schedule.

For guidance specific to fixed-dose tablets and options for dose flexibility, discuss alternatives with the GP or pharmacist.

Interaction Chart

Food, Alcohol And Lifestyle Interactions

Alcohol increases the risk of lactic acidosis with metformin and can potentiate hypoglycaemia with sulfonylureas.

Patients should be advised to moderate alcohol intake and discuss drinking patterns such as weekend drinking or binge episodes.

Caffeine and common Australian foods rarely alter the pharmacological effect, but large changes in carbohydrate intake will affect blood glucose control.

Common Drug‑Drug Interactions

Concomitant Drug Interaction Type Action Required
Corticosteroids Raise blood glucose Monitor glucose and consider dose adjustment.
Beta‑blockers May mask hypoglycaemia symptoms Counsel patient on recognising other signs of hypoglycaemia and monitor closely.
ACE Inhibitors / Diuretics Can affect glycaemic control or renal function Monitor renal function and glucose; adjust therapy as needed.
Cimetidine And Some Antibiotics May increase metformin levels Check interactions and adjust doses if necessary.
Iodinated Contrast Media Risk Of Acute Kidney Injury And Lactic Acidosis Stop metformin around the procedure per local protocols and check renal function.

Always provide a complete list of prescription medicines, herbal remedies and OTC products to the prescriber and pharmacist.

User Reports & Trends

Patient‑Reported Outcomes In Australia

  • Many patients report improved HbA1c compared with monotherapy when taking combination tablets.
  • Higher rates of hypoglycaemia are reported compared with metformin alone due to the sulfonylurea component.
  • Early GI upset is common from metformin, usually transient.
  • Some patients notice weight gain that may be attributable to the sulfonylurea.
  • Patients value the convenience of a one-tablet combination but note reduced flexibility for individual dose changes.

Adherence & Cost Behaviour

Australian patients often weigh PBS subsidy, pharmacy pricing and brand versus generic when choosing where to fill prescriptions.

Price sensitivity can affect adherence and lead to missed doses when cost is a barrier.

Coping Strategies:

  • Discuss PBS subsidy and possible alternatives with the GP.
  • Ask the pharmacist about concession pricing, generic alternatives or payment options.
  • Consider therapeutic alternatives if cost prevents adherence, with GP input.

Reporting Adverse Events

Report side effects to the GP or pharmacist promptly.

Adverse events should also be reported to the Therapeutic Goods Administration via the TGA Adverse Event Reporting system.

Access & Purchase Options

Where To Buy In Australia

  • Community pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart.
  • Local independent pharmacies.
  • Accredited online pharmacies with valid Australian dispensing arrangements.
  • Telehealth prescriptions that can be filled at the pharmacy of choice.

Access Checklist

  • Ensure a valid prescription is available.
  • Check the ARTG listing (Glucovance 500/5 is noted in the ARTG).
  • Confirm stock availability and ask about generic alternatives with the pharmacist.

In our online pharmacy, glucovance is available without a prescription, with discreet delivery to Australia in 9-21 days.

Telehealth & E‑Prescriptions

Telehealth is widely used in Australia and an e‑prescription can be sent to a nominated pharmacy.

Rural patients may face occasional supply delays and should ask the pharmacist to source stock or suggest nearby stockists.

PBS And Subsidy Considerations

Verify PBS listing and concession card eligibility before assuming a subsidy will apply.

If the prescribed product is not PBS-listed, discuss patient assistance or therapeutic alternatives with the GP.

Mechanism & Pharmacology

How The Combination Works

Metformin Hydrochloride
Reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity; usually does not cause hypoglycaemia when used alone.
Glyburide (Glibenclamide)
Stimulates pancreatic insulin secretion by closing pancreatic beta‑cell KATP channels; can cause hypoglycaemia.

ATC Classification: A10BD02 — metformin and sulfonylureas (glibenclamide/metformin) per WHO ATC mapping.

Clinical Pharmacology Points

The fixed‑dose combination provides complementary mechanisms to improve fasting and post‑prandial glucose control compared with monotherapy.

The combination carries an additive risk of hypoglycaemia due to the sulfonylurea component.

Weight gain is more likely than with metformin alone and is linked to sulfonylurea therapy.

Metformin exposure and safety depend on renal function and appropriate dosing adjustments.

Glyburide dosing must be cautious in older adults and in those with impaired renal function.

Indications & Off‑Label Uses

Approved Indications

  • Indicated for adults with type 2 diabetes as an adjunct to diet and exercise.
  • Used when monotherapy with metformin or a sulfonylurea is insufficient.
  • Appropriate when patients are already stable on the free combination of metformin and glibenclamide.

Off‑Label Considerations

Off‑label use is uncommon for this fixed‑dose combination.

Avoid use in type 1 diabetes and diabetic ketoacidosis.

Not recommended in pregnancy and breastfeeding without specialist advice.

Any off‑label prescribing should be documented, justified and discussed with the patient with extra monitoring and informed consent.

Patient Selection Checklist

  • Suitable when stable doses of both agents are required and fixed dosing is appropriate.
  • Renal function acceptable for metformin use.
  • Low risk of hypoglycaemia or a well‑educated patient able to recognise and manage hypoglycaemia.
  • Ability to attend regular monitoring for renal function and HbA1c.

Key Clinical Findings

Efficacy Vs Safety Balance

Outcome Benefit Common Harms Notes
HbA1c Reduction Greater reduction with combination therapy versus monotherapy Noted increased hypoglycaemia compared with metformin alone Useful when dual mechanisms are required
Weight Effects Improved glycaemic control may stabilise weight Weight gain can occur due to sulfonylurea Consider weight impact when choosing therapy
Cardiovascular Outcomes Metformin has established favourable effects on cardiometabolic risk Long-term CV data for sulfonylureas are variable Consider newer agents for comorbidity benefits

Evidence Interpretation For Australian Practice

Clinical trials and reviews show better glycaemic lowering with combination therapy than monotherapy.

However, combinations that include a sulfonylurea have higher hypoglycaemia incidence compared with metformin alone.

Metformin remains first-line for type 2 diabetes due to efficacy, safety and cardiometabolic profile.

When comorbidities such as cardiovascular disease or chronic kidney disease are present, consider agents with proven cardiorenal benefits as alternatives to sulfonylurea combinations.

Research Gaps & Monitoring Priorities

Ongoing monitoring should prioritise hypoglycaemia frequency, renal function and individualised glycaemic targets.

Refer to a diabetes specialist for complex or unstable cases.

Alternatives Matrix

Comparators Table

Drug / Class Indication Pros Cons PBS Status
Metformin Monotherapy Type 2 diabetes initial therapy Weight neutral; low hypoglycaemia risk GI side effects; renal dose limits Check PBS for current listings
Sulfonylureas (e.g. gliclazide) Second-line glucose lowering Effective; low cost Hypoglycaemia risk; weight gain Check PBS
DPP‑4 Inhibitors Type 2 diabetes add-on Low hypoglycaemia risk; oral dosing Smaller HbA1c reductions; cost Check PBS
SGLT2 Inhibitors Type 2 diabetes, with cardiorenal benefits Cardiorenal protection for many patients UTI / genital infection risk; cost Check PBS
GLP‑1 Receptor Agonists Type 2 diabetes, weight management Weight loss; cardiovascular benefit for some agents Injectable; cost Check PBS
Insulin When oral agents insufficient Powerful glucose lowering Injection therapy; hypoglycaemia risk; weight gain Check PBS

Pros & Cons Checklist

  • Metformin — pro: weight neutral and low hypoglycaemia risk; con: GI effects and renal limits.
  • Sulfonylureas — pro: effective and affordable; con: hypoglycaemia and weight gain.
  • SGLT2 Inhibitors — pro: cardiorenal benefits; con: risk of genitourinary infections and cost.
  • GLP‑1 Receptor Agonists — pro: weight loss and cardiovascular benefit for some; con: injectable and often costly.

Decision Support For Clinicians

Treatment choice should be tailored to comorbidities such as cardiovascular disease and chronic kidney disease.

Assess hypoglycaemia risk, cost considerations and patient preferences when selecting alternatives.

Document shared decision-making and review response to therapy regularly.

Common Questions

FAQs Seen In Australian Pharmacy Consultations

  • What Are Common Side Effects? — Gastrointestinal upset, a metallic taste and signs of hypoglycaemia; seek medical review for severe symptoms.
  • Can I Take With Other Diabetes Medicines? — Sometimes, but check with the GP or pharmacist for safe combinations and monitoring.
  • Pregnancy? — Not recommended; discuss preconception planning with an obstetrician.
  • How Often To Test Blood Glucose? — Individualised testing frequency is required; test more frequently when doses are changing or if hypoglycaemia occurs.

When To Contact Health Services

  • Seek urgent care for severe hypoglycaemia (loss of consciousness or seizures).
  • Seek urgent care for signs of lactic acidosis such as severe malaise, muscle pain, rapid breathing or profound drowsiness.
  • Contact a clinician for persistent vomiting or diarrhoea or any inability to eat or drink.

Documentation & Follow‑Up

Keep a record of home glucose readings, hypoglycaemia episodes and medication times.

Bring these records to GP and pharmacy reviews to aid dose adjustments and monitoring.

Price & Access Comparison

Suggested Comparison Table

Source Typical Price Range PBS Subsidy Status Prescription Requirement Delivery Options
Major Pharmacy Chain (e.g. Chemist Warehouse) — Check PBS Prescription required In-store pickup or delivery
Independent Local Pharmacy — Check PBS Prescription required Local delivery or pickup
Accredited Online Pharmacy — Check PBS Prescription required Discreet delivery
Telehealth + Pharmacy Dispense — Check PBS Prescription issued remotely Delivery to address or pharmacy pickup

Pharmacists should populate the table with current local pricing and subsidy details when advising patients.

Pharmacy / Source Checklist

  • Check ARTG and current stock status before dispensing.
  • Ask about generic alternatives and potential substitution options.
  • Request price match or concession pricing where available.
  • Consider delivery or rural sourcing options for patients outside metropolitan areas.

Patient Tips To Reduce Cost

  • Ask the GP about PBS-substitutable alternatives if affordability is an issue.
  • Use concession card discounts where eligible.
  • Discuss staged therapy or therapeutic alternatives with the prescriber to balance cost and efficacy.
  • Check whether community health services offer support for medication costs.

Registration & Regulation

TGA & ARTG Status

  • GLUCOVANCE 500/5 tablets are recorded in the Australian Register of Therapeutic Goods (ARTG) as a marketed product in Australia.
  • To verify registration, search the TGA ARTG database online and confirm current product details and sponsor information.
  • Ask the pharmacist to confirm ARTG entry and any changes to product listing if in doubt.

Reporting & Pharmacovigilance

Report adverse events to the Therapeutic Goods Administration to support national pharmacovigilance.

Pharmacists should maintain records of reported events and inform prescribers of emerging safety signals.

PBS Subsidy & Prescribing Rules

PBS listings change over time and prescribers should check the PBS schedule for current subsidy status and authority requirements.

Ensure prescriptions meet regulatory requirements for repeats and substitution rules at the time of dispensing.

Storage & Handling

Household Storage Advice

  • Store tablets in the original blister packaging where possible.
  • Aim to keep below 25°C and away from moisture and high heat; avoid bathroom storage.
  • Protect from direct sunlight and do not leave medicines in a hot car.
  • Keep all medicines out of reach and sight of children and pets.
  • Australian summers can be hot and humid, so avoid prolonged storage in non‑climate-controlled areas.

Pharmacy Storage And Dispensing

Glucovance tablets do not require cold-chain storage.

Pharmacies should protect stock from excessive heat and humidity and rotate stock using expiry dates.

Disposal & Returns

Return expired or unwanted tablets to a local chemist take-back program or council medication collection.

Do not flush medicines down the toilet or discard in household rubbish where avoidable.

Guidelines For Proper Use & Pharmacist Counselling

Pharmacist Counselling Checklist

  • Explain the indication and that the product contains metformin and glyburide (glibenclamide).
  • Advise taking tablets with food to reduce GI upset and hypoglycaemia risk.
  • Describe the signs of hypoglycaemia and rescue measures including fast-acting carbohydrates and glucagon where appropriate.
  • Advise when to withhold treatment — acute illness, impending contrast imaging procedures or inability to eat.
  • Arrange regular renal function monitoring and HbA1c checks as part of follow-up.

Patient Education Materials & Follow‑Up

Provide a written hypoglycaemia action plan tailored to the patient’s treatment and lifestyle.

Recommend referral to a diabetes educator or dietitian for structured education and meal planning.

Book follow-up medication reviews to reassess efficacy, side effects and adherence.

Links To Australian Guidance

Reference national guidance such as Diabetes Australia and RACGP management pathways when counselling patients.

Integrate PBS and TGA checks into routine pharmacy counselling to ensure up-to-date regulatory information.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 14-21 days
Wollongong New South Wales 14-21 days
Geelong Victoria 14-21 days
Cairns Queensland 14-21 days
Townsville Queensland 14-21 days

Final Notes

This article covers the fixed-dose combination of metformin hydrochloride and glibenclamide marketed as GLUCOVANCE in Australia.

Use the ARTG and PBS resources and consult the prescriber when uncertainties arise about indications or subsidy status.

For ongoing medication supply and personalised advice, speak to the local pharmacist or GP and ensure scheduled monitoring is maintained.

Related products